U.S. Payrolls Seen Rebounding in August as Labor Market Stays Soft 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Dollar Hits Two-Week High as Iran Conflict Lifts Oil and Bond Yields 
Gold Prices Hold Near $4,400 as Fed Rate Hike Bets Ease 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Oil Prices Surge as U.S.-Iran Conflict Threatens Hormuz Supply 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Chinese AI Stocks Rally After OpenAI Launches GPT-6 Astra 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Treasury Yields Set to Stay High as Debt Supply Pressures Bond Market 
Gold Prices Hold Near $4,500 as Fed Rate Hike Bets Ease 
US Strikes Iran IRGC Targets as Conflict Escalates 
Add as a preferred source on Google
Lotte Biologics has completed the acquisition process to take over the manufacturing facility of Bristol Myers Squibb in Syracuse, New York, for $160 million. The drug manufacturing unit of the Lotte Group confirmed the deal on Tuesday, Jan. 3.
With the addition of Bristol Myers Squibb’s plant in Lotte Biologics’ property portfolio, the fifth-largest retail-chemical company in South Korea has officially jumped into the contract manufacturing business. This acquisition also comes after the Lotte Group launched Lotte Biologics, a biological CDMO (Contract Development Manufacturing Organization), in June 2022.
As per The Korea Herald, the company actually completed the takeover of the Bristol Myers Squibb facility on Dec. 31. All of its existing manufacturing contract agreements for drug production are also included in the acquisition. It was reported that these deals are worth $220 million and deliveries are to be carried out over the next three years.
The South Korean CDMO firm also revealed its plans to invest $70 million to upgrade the manufacturing facility in Syracuse. This investment will add manufacturing lines for drug substances, antibody-drug conjugates, and other drug products.
As Lotte Biologics buys Bristol Myers Squibb's manufacturing facility, it will also be creating around 70 jobs, and they will be assigned to various roles at the plant. This will be an addition to the existing BMS workforce, which is said to be 450 in number.
“Based on the successful acquisition of the Syracuse Plant, Lotte Biologics will emerge as a global CDMO that can achieve 1.5 trillion KRW in sales, a 30% operating margin, and a corporate value of 20 trillion KRW by 2030 by providing innovative medicines to patients,” Lotte Biologics’ chief executive officer, Richard Lee, said in a press release. “We will continue to grow at a rapid pace.”
The CEO further said that his goal is to successfully establish the company as a new growth engine for the Lotte Group. Lee will work on achieving this ambition by signing partnership deals with some global pharmaceutical companies and securing other bio ventures.
